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Case Summary Continued: Clinical Deterioration
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In July of 2019, a new respiratory illness emerged as a cluster of healthy, young adolescents
developed profound hypoxic respiratory failure. Investigation revealed that it was related to
e-cigarette and vaping use. A new clinical syndrome of e-cigarette and vaping useassociated lung injury (EVALI) emerged. Its development was linked to
tetrahydrocannabinol (THC) use and Vitamin E acetate [1]. We present a case of vaping
associated lung injury, resulting in severe acute respiratory distress syndrome with eventual,
unexplained cardiovascular collapse and death.

Case Summary
• Patient is a 37 year-old male with migraines, obesity (BMI 34), chronic
back pain, and tetrahydrocannabinol (THC) vaping who presented with
fever, shortness of breath, and altered mental status.
• He arrived in distress, febrile, tachycardic, tachypneic, and profoundly
hypoxic on room air
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• Initial blood gas confirmed profound hypoxemia: pH 7.33, PCO2 35.5, PO2
32.9, and saturation of 63.8 with a lactate of 8.6 mmol/L.
• His initial labs are listed in Table 1.
• Initial chest x-ray showed bilateral infiltrates.
• He was trialed on CPAP, but remained hypoxic, requiring intubation and
mechanical ventilation. His initial PaO2 to FI02 ratio was 111 on a PEEP of
12, consistent with moderate ARDS.
• He was treated empirically with vancomycin, piperacillin / tazobactam, and
azithromycin.
• Infectious work-up showed a negative influenza and viral respiratory panel
(BioFire) PCR. Respiratory culture grew few non-pneumoniae Streptococcus.
Blood cultures were negative. Bronchoscopy showed diffuse, pink frothy
secretions in the upper airways with bronchoalveolar lavage (BAL) growing
commensal flora.
• There were no exam findings of autoimmune disease including synovitis,
rash, erythema nodosum, etc. Laboratory data was without hemolysis. A
peripheral smear was without schistocytes or spherocytes.
• Echocardiogram revealed a preserved EF (58%) with normal LV size and
thickness and a negative bubble study, ruling out intracardiac shunt. It did
show a mildly enlarged right ventricle and mildly reduced global RV systolic
function with PAP of 42 mmHg and mild tricuspid regurgitation.
• A computed tomography (CT) of the chest with contrast was also obtained
and negative for pulmonary embolism, but demonstrated extensive, bilateral
ground glass and airspace opacities consistent with radiograph findings of
EVALI [2] Figure 1.
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Figure 1: CT chest with contrast showing extensive ground glass and airspace opacities
in (a) coronal and (b) axial slices of the lungs

Table One: Laboratory Values
Lab

Value

Table Two: Criteria for Diagnosis of EVALI
WBC (K/uL)

17.3

Absolute Neutrophils (K/uL)

15.60

D-dimer (ug/mL FEU)

3.03

C-Reactive Protein (mg/dL)

29.0

Procalcitonin (ng/mL)

2.69

BNP (pg/mL)

135

PaO2 (mmHg)

32.9

Lactate (mmol/L)

8.6

High Sensitivity Troponin (ng/L)
(following decompensation)

>20,000

Table 1: Laboratory Values on initial presentation

•
•
•

E-cigarette or vaping use within last 90 days
Lung opacities on chest radiograph or CT imaging
Exclusion of lung infection
- Negative influenza testing
- Negative viral respiratory panel
- If clinically indicated, negative testing for Legionella and Streptococcus
pneumoniae, blood cultures, sputum culture, bronchoalveolar lavage, and
testing for HIV-related opportunistic infections
• No likely alternative diagnosis (cardiac, rheumatologic, etc.)

Discussion
This patient fulfills diagnostic criteria for EVALI listed in Table 2, including e-cigarette use
within the last 90 days, lung opacities on chest radiograph or CT, exclusion of lung
infection, and absence of alternative diagnosis [3]. This case report highlights an instance of
acute cardiovascular collapse in a patient with EVALI after initial course of improvement
and extended treatment with antibiotics and steroids. Studies have shown certain clinical
characteristics such as asthma, cardiac disease or psychiatric conditions place patients at
greater risk of hospitalization and mortality in EVALI [4,5]. Patients recovering from
EVALI, particularly those with chronic medical conditions, should undergo close monitoring
for rapid deterioration with a low threshold to resume treatment in the appropriate clinical
setting.
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Given his overall clinical picture including bilateral infiltrates and vaping of
THC, there was a high suspicion for EVALI.
• He was started on methylprednisolone at 1 mg/kg/day and completed a 14day course of both steroids and antibiotics.
• He gradually improved with diuresis and was extubated on hospital day 13.

• However, on Hospital Day 15, he decompensated
• He became tachycardic, tachypneic, and was re-intubated.
• He remained profoundly tachycardic and developed shock requiring
vasopressors.
• He developed new EKG changes with ST elevations, reciprocal depressions,
and a significant troponin elevation. Figure 2.
• While the cardiac catheterization lab was being activated, the patient
suffered a PEA arrest.
• Cardiac catheterization was emergently performed which demonstrated nonobstructed coronary arteries and patent pulmonary vasculature.
• He was initiated on veno-arterial extracorporeal membrane oxygenation (VA
ECMO).
• Over the next 12 hours, the patient further decompensated developing multiorgan failure with increasing vasopressor requirements despite VA ECMO
support. Due to his poor prognosis, the decision was ultimately made to
withdraw care.

Figure 2. EKG on admission (left) and prior to arrest (right) showing ST elevations in
AVR and V1 with diffuse depressions in I, AVL, V3-V6, and II
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